Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
<h4>Purpose</h4>Uveal melanoma (UM) is associated with a high risk of metastases and lack of efficient therapies. Reduced capacity for apoptosis induction by chemotherapies is one obstacle to efficient treatments. Human UM is characterized by high expression of the anti-apoptotic protein...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/76fbfa490b634f1296b2e0f84faf5e90 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:76fbfa490b634f1296b2e0f84faf5e90 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:76fbfa490b634f1296b2e0f84faf5e902021-11-18T08:37:59ZTargeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.1932-620310.1371/journal.pone.0080836https://doaj.org/article/76fbfa490b634f1296b2e0f84faf5e902014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24454684/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Purpose</h4>Uveal melanoma (UM) is associated with a high risk of metastases and lack of efficient therapies. Reduced capacity for apoptosis induction by chemotherapies is one obstacle to efficient treatments. Human UM is characterized by high expression of the anti-apoptotic protein Bcl-2. Consequently, regulators of apoptosis such as Bcl-2 family inhibitors may constitute an attractive approach to UM therapeutics. In this aim, we have investigated the efficacy of the Bcl-2/Bcl-XL inhibitor S44563 on 4 UM Patient-Derived Xenografts (PDXs) and derived-cell lines.<h4>Experimental design</h4>Four well characterized UM PDXs were used for in vivo experiments. S44563 was administered alone or combined with fotemustine either concomitantly or after the alkylating agent. Bcl-2, Bcl-XL, and Mcl-1 expressions after S44563 administration were evaluated by immunohistochemistry (IHC).<h4>Results</h4>S44563 administered alone by at 50 and 100 mg/kg i.p. induced a significant tumour growth inhibition in only one xenograft model with a clear dose effect. However, when S44563 was concomitantly administered with fotemustine, we observed a synergistic activity in 3 out of the 4 tested models. In addition, S44563 administered after fotemustine induced a tumour growth delay in 2 out of 3 tested xenografts. Finally, IHC analyses showed that Bcl-2, Bcl-XL, and Mcl-1 expression were not modified after S44563 administration.<h4>Conclusion</h4>The novel anti-apoptotic experimental compound S44563, despite a relative low efficacy when administered alone, increased the efficacy of fotemustine in either concomitant or sequential combinations or indeed subsequent to fotemustine. These data support further exploration of potential therapeutic effect of Bcl-2/Bcl-xl inhibition in human UM.Fariba NématiCatherine de MontrionGuillaume LangLaurence Kraus-BerthierGuillaume CaritaXavier Sastre-GarauAurélie BerniardDavid VallerandOlivier GenesteLudmilla de PlaterAlain PierréBrian LockhartLaurence DesjardinsSophie Piperno-NeumannStéphane DepilDidier DecaudinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 1, p e80836 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Fariba Némati Catherine de Montrion Guillaume Lang Laurence Kraus-Berthier Guillaume Carita Xavier Sastre-Garau Aurélie Berniard David Vallerand Olivier Geneste Ludmilla de Plater Alain Pierré Brian Lockhart Laurence Desjardins Sophie Piperno-Neumann Stéphane Depil Didier Decaudin Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. |
| description |
<h4>Purpose</h4>Uveal melanoma (UM) is associated with a high risk of metastases and lack of efficient therapies. Reduced capacity for apoptosis induction by chemotherapies is one obstacle to efficient treatments. Human UM is characterized by high expression of the anti-apoptotic protein Bcl-2. Consequently, regulators of apoptosis such as Bcl-2 family inhibitors may constitute an attractive approach to UM therapeutics. In this aim, we have investigated the efficacy of the Bcl-2/Bcl-XL inhibitor S44563 on 4 UM Patient-Derived Xenografts (PDXs) and derived-cell lines.<h4>Experimental design</h4>Four well characterized UM PDXs were used for in vivo experiments. S44563 was administered alone or combined with fotemustine either concomitantly or after the alkylating agent. Bcl-2, Bcl-XL, and Mcl-1 expressions after S44563 administration were evaluated by immunohistochemistry (IHC).<h4>Results</h4>S44563 administered alone by at 50 and 100 mg/kg i.p. induced a significant tumour growth inhibition in only one xenograft model with a clear dose effect. However, when S44563 was concomitantly administered with fotemustine, we observed a synergistic activity in 3 out of the 4 tested models. In addition, S44563 administered after fotemustine induced a tumour growth delay in 2 out of 3 tested xenografts. Finally, IHC analyses showed that Bcl-2, Bcl-XL, and Mcl-1 expression were not modified after S44563 administration.<h4>Conclusion</h4>The novel anti-apoptotic experimental compound S44563, despite a relative low efficacy when administered alone, increased the efficacy of fotemustine in either concomitant or sequential combinations or indeed subsequent to fotemustine. These data support further exploration of potential therapeutic effect of Bcl-2/Bcl-xl inhibition in human UM. |
| format |
article |
| author |
Fariba Némati Catherine de Montrion Guillaume Lang Laurence Kraus-Berthier Guillaume Carita Xavier Sastre-Garau Aurélie Berniard David Vallerand Olivier Geneste Ludmilla de Plater Alain Pierré Brian Lockhart Laurence Desjardins Sophie Piperno-Neumann Stéphane Depil Didier Decaudin |
| author_facet |
Fariba Némati Catherine de Montrion Guillaume Lang Laurence Kraus-Berthier Guillaume Carita Xavier Sastre-Garau Aurélie Berniard David Vallerand Olivier Geneste Ludmilla de Plater Alain Pierré Brian Lockhart Laurence Desjardins Sophie Piperno-Neumann Stéphane Depil Didier Decaudin |
| author_sort |
Fariba Némati |
| title |
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. |
| title_short |
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. |
| title_full |
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. |
| title_fullStr |
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. |
| title_full_unstemmed |
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. |
| title_sort |
targeting bcl-2/bcl-xl induces antitumor activity in uveal melanoma patient-derived xenografts. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/76fbfa490b634f1296b2e0f84faf5e90 |
| work_keys_str_mv |
AT faribanemati targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT catherinedemontrion targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT guillaumelang targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT laurencekrausberthier targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT guillaumecarita targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT xaviersastregarau targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT aurelieberniard targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT davidvallerand targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT oliviergeneste targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT ludmilladeplater targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT alainpierre targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT brianlockhart targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT laurencedesjardins targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT sophiepipernoneumann targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT stephanedepil targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts AT didierdecaudin targetingbcl2bclxlinducesantitumoractivityinuvealmelanomapatientderivedxenografts |
| _version_ |
1718421507079667712 |